Related Experiment Video
Updated: Aug 7, 2026

Detecting Anastasis In Vivo by CaspaseTracker Biosensor
Published on: February 1, 2018
Cytoskeletal actin degradation induced by lovastatin in cardiomyocytes is mediated through caspase-2
Jennifer Y Kong1, Simon W Rabkin
1University of British Columbia, Room D404, 2733 Heather Street, Vancouver, B.C. V5Z 3J5, Canada.
Abstract:
The objective of this study was to test the hypothesis that cytoskeletal actin fragmentation is mediated through caspase-2, specifically examining the ability of a caspase-2 inhibitor to interfere with actin fragmentation, in comparison with a caspase-3 inhibitor. Cardiomyocytes were cultured from embryonic chick heart. The fine structural element of cellular F-actin was visualized by staining cardiomyocytes with NBD-phallacidin. Lovastatin induced a dramatic and concentration-dependent loss of intact F-actin. The selectivity of this effect of lovastatin was demonstrated by the absence of similar changes in F-actin when cardiomyocytes were treated with the apoptotic stimulus palmitate, the metabolism of which produces acetyl CoA, the early substrate of cholesterol synthesis, through the mevalonate pathway. FACS analysis of NBD-phallacidin-stained cells was used to quantify the amount of F-actin loss. Actin fragmentation produced by lovastatin was operative through a caspase-2 pathway, as the caspase-2 inhibitor, z-VDVAD-fmk, significantly blocked lovastatin-induced changes in F-actin, but the caspase-3 inhibitor, Ac-DEVD-CHO, did not. Interruption of the mevalonate pathway was in part responsible for lovastatin's action, as the downstream metabolite mevalonate partially reversed the effect of lovastatin on actin fragmentation. These data indicate a previously unrecognized link between cytoskeletal actin and caspase-2.
Insights
Lovastatin causes cytoskeletal actin fragmentation via caspase-2, not caspase-3. This effect, linked to the mevalonate pathway, highlights a new connection between actin and caspase-2 in heart cells.
Area of Science:
- Cell Biology
- Biochemistry
- Cardiovascular Research
Background:
- Cytoskeletal actin integrity is crucial for cellular structure and function.
- Caspases are key mediators of apoptosis, but their roles in non-apoptotic cellular processes are increasingly recognized.
- Lovastatin, a cholesterol-lowering drug, has known cellular effects beyond lipid metabolism.
Purpose of the Study:
- To investigate the role of caspase-2 in lovastatin-induced cytoskeletal actin fragmentation.
- To compare the involvement of caspase-2 versus caspase-3 in this process.
- To explore the link between the mevalonate pathway and actin fragmentation.
Main Methods:
- Cultured embryonic chick cardiomyocytes.
- F-actin visualization using NBD-phallacidin staining.
- Quantification of F-actin loss via Fluorescence-Activated Cell Sorting (FACS) analysis.
- Treatment with lovastatin, palmitate, caspase-2 inhibitor (z-VDVAD-fmk), and caspase-3 inhibitor (Ac-DEVD-CHO).
- Assessment of mevalonate's effect on actin fragmentation.
Main Results:
- Lovastatin induced a dose-dependent loss of F-actin in cardiomyocytes.
- This actin fragmentation was specifically mediated by caspase-2, as a caspase-2 inhibitor blocked the effect, while a caspase-3 inhibitor did not.
- Palmitate, an apoptotic stimulus, did not cause similar F-actin changes.
- Interruption of the mevalonate pathway contributed to lovastatin's action, with mevalonate partially reversing the actin fragmentation.
Conclusions:
- Cytoskeletal actin fragmentation by lovastatin is mediated through a caspase-2-dependent pathway.
- This study reveals a novel link between cytoskeletal actin dynamics and caspase-2 activation.
- The mevalonate pathway plays a partial role in lovastatin's effects on cellular actin.
Related Concept Videos
Cytoskeletal Accessory Proteins
Actin Filament Depolymerization
In F-actin, the ADF/cofilin proteins...
The Role of Actin and Myosin in Non-muscle Cells
Cell Motility through Blebbing
Blebbing Through the Matrix
In multicellular...
Caspases

